The European Registry on XXXX (EUROAPS): A survey of 247 consecutive cases.

@entity1 @entity532 @entity1252 @entity1701 @entity12009 @entity715
AIM: To analyse the clinical features, laboratory data, foetal-maternal outcomes, and follow-up in a cohort of 247 @entity1 with @entity1701 ( @entity1701 ). METHODS: The European Registry on @entity12009 became a Registry within the framework of the European Forum on Antiphospholipid Antibody projects and placed on a website in June 2010. Cases with obstetric complaints related to aPL who tested positive for aPL prospectively and retrospectively were included. The three-year survey results are reported. RESULTS: 338 @entity1 with 1253 pregnancy episodes were included; 915 were historical and 338 were latest episodes. All these @entity1 tested positive for aPL. 247 of the 338 fulfilled the Sydney criteria. According to the laboratory categories, 84/247 were in category I, 42 in IIa, 66 in IIb and 55 in IIc. @entity532 other than foetal losses, appeared in 129 cases (52.2%). 192 (77.7%) had a live birth and 55 (22.3%) did not. The latter group of only 38 cases (69%) received adequate treatment and 17 (31%) did not. 177/247 (72%) @entity1 were put on heparin plus LDA. @entity715 appeared in two during pregnancy and in 14 during the puerperium. 7 (3%) @entity1 evolved to complete @entity1252 . CONCLUSIONS: @entity1701 shows differential characteristics than classical @entity12009 . All laboratory test categories are needed to avoid false-negative diagnoses. In some cases, complement levels could act as a serological marker. @entity1701 has very good foetal-maternal outcomes when treated. @entity715 and progression to @entity1252 in mothers with @entity1701 are scarce compared with "classical @entity12009 ", suggesting that they have different aPL-mediated pathogenic mechanisms.
